ECM
AGRX

Endurant Capital Management’s Agile Therapeutics AGRX Stock Holding History

Endurant Capital Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-221
Closed -$1.97M – 98
2017
Q3 		$1.97M Buy
+221
New +$1.7M 0.6% 57

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Endurant Capital Management's AGRX Position: Q4 2017 in Review

Endurant Capital Management sold out of Agile Therapeutics (AGRX) in Q4 2017, closing a stake of 221 shares — an estimated $1.97M sold.

Endurant Capital Management first reported a position in AGRX in Q3 2017 and held it in 1 quarter. The position peaked at $1.97M in Q3 2017. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2017.

  • Endurant Capital Management reported no remaining Agile Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Endurant Capital Management sold 221 Agile Therapeutics shares in Q4 2017, an estimated $1.97M.
  • Endurant Capital Management first reported a position in Agile Therapeutics in Q3 2017 and held it in 1 quarter.
  • Endurant Capital Management's Agile Therapeutics position peaked at $1.97M in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2017.

Based on Endurant Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.